Lire l’article<\/a> (en anglais)<\/p>\n","protected":false},"excerpt":{"rendered":"Dans cette \u00e9tude de phase 1\/2, le carfilzomib a \u00e9t\u00e9 ajout\u00e9 \u00e0 un conditionnement \u00e0 base de melphalan \u00e0 haute dose avant une autogreffe de cellules souches (ASCT) chez des patients atteints de my\u00e9lome multiple qui avaient \u00e9t\u00e9 trait\u00e9s avec \u22642 lignes de traitement ant\u00e9rieures. Lire l’article (en anglais)<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11094","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11094"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11094\/revisions"}],"predecessor-version":[{"id":31258,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11094\/revisions\/31258"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}